New hormone pathway: FGF21
Scientists reported that the natural hormone FGF21 reversed obesity in mice by activating a hindbrain circuit that is separate from GLP‑1 signaling. (sciencedaily.com) ScienceDaily said the discovery identifies a distinct neural route for appetite and weight control in preclinical models. (sciencedaily.com)
A hormone called fibroblast growth factor 21, or FGF21, helped obese mice lose weight by switching on a hindbrain circuit that is different from the one used by GLP-1 drugs. (cell.com) Hormones are chemical messengers that carry instructions through the blood, and FGF21 is one the body already makes to help manage energy use. In this study, University of Oklahoma researchers traced its weight-loss effects to the lower back part of the brain, not the hypothalamus they expected to find. (ouhsc.edu) The paper was published in *Cell Reports* in 2026 as article 117093, with Matthew Potthoff of the OU College of Medicine as lead author. The team reported that pharmacological FGF21 reversed obesity in mice and raised energy expenditure, a measure of how much fuel the body burns. (sciencedaily.com) The key brain stations were the nucleus of the solitary tract and the area postrema, two hindbrain regions that process body signals such as fullness, nausea, and metabolism. Those regions then relayed the signal to the parabrachial nucleus, and the study said that link was necessary for FGF21’s metabolic effects. (ouhsc.edu) That matters because GLP-1 medicines such as semaglutide also act through hindbrain neurons, but through a different route. A 2024 *Nature* paper found separate hindbrain GLP-1 receptor circuits for satiety and aversion, with nucleus of the solitary tract neurons tied to fullness and area postrema neurons tied to aversion. (nature.com) The Oklahoma team said FGF21 and GLP-1 do not produce weight loss the same way even when they act in the same general neighborhood of the brain. GLP-1 lowers food intake, while FGF21 appears to push metabolism higher, burning more energy and reducing body weight in mice. (medicalxpress.com) FGF21 is already part of drug development beyond obesity. The university said drugs aimed at the FGF21 pathway are in clinical trials for metabolic dysfunction-associated steatohepatitis, or MASH, a serious fatty liver disease linked to obesity and insulin resistance. (ouhsc.edu) The study does not show that FGF21 reverses obesity in people, and Potthoff said more work is needed to test whether the same circuit also explains FGF21’s effects on MASH. He also said FGF21 analogs can bring gastrointestinal side effects and, in some cases, bone loss. (sciencedaily.com) For now, the result is a map, not a medicine: a naturally occurring hormone, a defined hindbrain pathway, and a mouse study that points to a second neural route for controlling body weight. (cell.com)
